Arachidonic acid-stimulated platelet tests: Identification of patients less sensitive to aspirin treatment

References

• Floyd CN, Ferro A. Mechanisms of aspirin resistance. Pharmacol Ther 2014;141:69–78
   PubMed Web of Science ®Google Scholar
• Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta-analysis. Arch Intern Med 2007;167:1593–1599
   PubMed Web of Science ®Google Scholar
• Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: Systematic review and meta-analysis. BMJ 2008;336:195–198
   PubMed Web of Science ®Google Scholar
• Frelinger AL, III Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009;120:2586–2596
   PubMed Web of Science ®Google Scholar
• Pulcinelli FM, Biasucci LM, Riondino S, Giubilato S, Leo A, Di Renzo L, Trifiro E, Mattiello T, Pitocco D, Liuzzo G, et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J 2009;30:1279–1286
   PubMed Web of Science ®Google Scholar
• Mattiello T, Guerriero R, Lotti LV, Trifiro E, Felli MP, Barbarulo A, Pucci B, Gazzaniga P, Gaudio C, Frati L, et al. Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: Evidence of a reduced drug action in patients after coronary artery bypass grafting. J Am Coll Cardiol 2011;58:752–761
   PubMed Web of Science ®Google Scholar
• Weber AA, Przytulski B, Schanz A, Hohlfeld T, Schror K. Towards a definition of aspirin resistance: A typological approach. Platelets 2002;13:37–40
   PubMed Web of Science ®Google Scholar
• Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809–1817
   PubMed Web of Science ®Google Scholar
• Su G, Wang Z, Ding Y. Association of the platelet membrane glycoprotein I a C807T gene polymorphism with aspirin resistance. J Huazhong Univ Sci Technolog Med Sci 2007;27:664–667
   PubMed Web of Science ®Google Scholar
• Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, Testa L, Sheiban I, Sangiorgi G. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006;27:2667–2674
   PubMed Web of Science ®Google Scholar
• Kasmeridis C, Apostolakis S, Lip GY. Aspirin and aspirin resistance in coronary artery disease. Curr Opin Pharmacol 2013;13:242–250
   PubMed Web of Science ®Google Scholar
• Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, Pulcinelli FM, Cerletti C, Rao AK. Aspirin resistance: Position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005;3:1309–1311
   PubMed Web of Science ®Google Scholar
• Linden MD, Tran H, Woods R, Tonkin A. High platelet reactivity and antiplatelet therapy resistance. Semin Thromb Hemost 2012;38:200–212
   PubMed Web of Science ®Google Scholar
• Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230–235
   PubMed Web of Science ®Google Scholar
• Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961–965
   PubMed Web of Science ®Google Scholar
• Pulcinelli FM, Gresele P, Bonuglia M, Gazzaniga PP. Evidence for separate effects of U73122 on phospholipase C and calcium channels in human platelets. Biochem Pharmacol 1998;56:1481–1484
   PubMed Web of Science ®Google Scholar
• Born GVR. The aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927–929
   PubMed Web of Science ®Google Scholar
• Cerletti C, Dell'Elba G, Manarini S, Pecce R, Di Castelnuovo A, Scorpiglione N, Feliziani V, de Gaetano G. Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Clin Pharmacokinet 2003;42:1059–1070
   PubMed Web of Science ®Google Scholar
• Lordkipanidze M. Advances in monitoring of aspirin therapy. Platelets 2012;23:526–536
   PubMed Web of Science ®Google Scholar
• Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702–1708
   PubMed Web of Science ®Google Scholar
• Grove EL, Hvas AM, Johnsen HL, Hedegaard SS, Pedersen SB, Mortensen J, Kristensen SD. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010;103:1245–1253
   PubMed Web of Science ®Google Scholar
• Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004;110:e489–493
   PubMed Web of Science ®Google Scholar
• Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, Fitzgerald DJ. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005;46:1258–1263
   PubMed Web of Science ®Google Scholar
• Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pagliaccia F, Pocaterra D, Ragazzoni E, Rolandi G, Rocca B, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012;119:3595–3603
   PubMed Web of Science ®Google Scholar
• Awtry EH, Loscalzo J. Aspirin. Circulation 2000;101:1206–1218
   PubMed Web of Science ®Google Scholar
• Wurtz M, Wulff LN, Grove EL, Kristensen SD, Hvas AM. Influence of renal function and platelet turnover on the antiplatelet effect of aspirin. Thromb Res 2012;129:434–440
   PubMed Web of Science ®Google Scholar
• Timur AA, Murugesan G, Zhang L, Barnard J, Bhatt DL, Kottke-Marchant K. Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy. Thromb Res 2014;134:96–104
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US. Evaluation of dose-related effects of aspirin on platelet function: Results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007;115:3156–3164
   PubMed Web of Science ®Google Scholar
• Gorog DA, Fuster V. Platelet function tests in clinical cardiology: Unfulfilled expectations. J Am Coll Cardiol 2013;61:2115–2129
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Cerletti C, Harrison P, Hayward CP, Kenny D, Nugent D, Nurden P, Rao AK, Schmaier AH, Watson SP, et al. Recommendations for the Standardization of Light Transmission Aggregometry: A Consensus of the Working Party from the Platelet Physiology Subcommittee of SSC/ISTH. J Thromb Haemost 2013;11:1183–1189
   Web of Science ®Google Scholar